Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, since a warm and shiny sun is enveloping the quiet Pharmalot campus. Our short person has left for the local schoolhouse and our mascots are comfortably snoozing in their respective corners. As for us, we are, as usual, keeping busy by looking for interesting items and having interesting conversations. Have something to say? Drop us a line. Meanwhile, here are some tidbits. Hope you conquer the world today …

Spark Therapeutics (ONCE), whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug outside the U.S. to Novartis (NVS) for up to $170 million, Reuters notes. Spark will keep U.S. rights to Luxturna, which is the first approved gene therapy for an inherited disease. The company plans to launch the one-time treatment in March, charging an unprecedented $850,000.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!